Market Place
Sourcing Support
Genethon to Start EU Pivotal Trial for Duchenne Therapy GNT0004
28 Jul 2025 //
BUSINESSWIRE
Hansa Biopharma reports Q2 and Jan-June 2025 financial results
17 Jul 2025 //
PR NEWSWIRE
Genethon Highlights Atamyo`s Gene Therapy, LGMD Progress
19 Jun 2025 //
BUSINESSWIRE
Genethon Presents Two Year Results of Gene Therapy Trial for DMD
19 May 2025 //
BUSINESSWIRE
Hansa Biopharma Reports Q1 and Jan-Mar 2025 Financial Results
24 Apr 2025 //
PR NEWSWIRE
Genethon Marks Rare Disease Day With Advances In Gene Therapies
27 Feb 2025 //
BUSINESSWIRE
Genethon & Eukarÿs Partner To Low manufacture Cost For Gene Therapy
23 Jan 2025 //
GLOBENEWSWIRE
Genethon Highlight DMD Gene Therapy, AAV Trial, AI Capsid for 2024
19 Dec 2024 //
BUSINESSWIRE
Genethon, Hansa Begin Phase 2 for Imlifidase in Crigler-Najjar
03 Dec 2024 //
PR NEWSWIRE
Genethon Present Results for Duchenne Gene Therapy at ASGCT
19 Nov 2024 //
BUSINESSWIRE
Genethon Updates On Gene Therapy For Duchenne Muscular Dystrophy
06 Sep 2024 //
BUSINESSWIRE
Genethon`s DMD Gene Therapy, Atamyo`s LGMD, Cardiomyopathy Advances
03 Jun 2024 //
BUSINESSWIRE
GNT0004 Gene Therapy for DMD Results at Myology 2024 Congress
23 Apr 2024 //
BUSINESSWIRE
Genethon Pursues Strategies for Ensuring Patient Access to Gene Therapies
29 Feb 2024 //
BUSINESSWIRE
Genethon Announces Publication of Clinical Trial Results of a Gene Therapy
17 Nov 2023 //
BUSINESSWIRE
Phase 1/2 Trial Results of Genethon’s Gene Therapy for Crigler-Najjar Syndrome
22 Aug 2023 //
BUSINESSWIRE
GenoTher Biocluster Designation Bolsters French Leadership in Gene Therapy
10 Jul 2023 //
BUSINESSWIRE
Genethon Given PRIME Status by EMA for Gene Therapy
07 Mar 2023 //
BUSINESSWIRE
Genethon Launches Pivotal Trial of Gene Therapy for Crigler-Najjar Syndrome
10 Jan 2023 //
BUSINESSWIRE
Pfizer, Sarepta team with DMD gene therapy makers for analysis
18 May 2022 //
FIERCEBIOTECH
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.